1

Corporate Presentation

Cameron Groome, CEO & PresidentJuly, 2014

2

Forward Looking StatementsThis presentation includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including

those identified by the expressions “can”, “potentially”, “would”, anticipate", "believe", "estimate", and similar expressions. The forward-looking statements reflect the current expectations of Avivagen Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen assumes no

obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

3

Company Highlights

Two Technologies with Large Sales Potential

1. Enhancement of Immunity against bacteria– Discovery of a new class of natural compounds

– As an alternative to the use of antibiotics in livestock feeds

– As a health supplement for companion animals

2. Permanent Non-Surgical Sterilization– Means to replace spaying for population control

– Potentially applicable to all female mammals

– Uses for dogs, cats, feral/wild animals and livestock

4

1st Tech: Immune Enhancement

• Discovery of Oxidized Carotenoids (OxC-beta)– Previously un-recognized natural compounds– Increase expression of bacterial recognition receptors– Help maintain optimal health and growth

• Development of Novel and Proprietary Products– Extensive patent portfolio– Livestock feeding protocols under development– Being sold as pet health supplements in the U.S.

5

1st Tech: Livestock Feed Product

• For inclusion into prepared feeds

• Active at parts-per-million levels and a cost effective alternative to prophylactic use of antibiotics

• Shown to work across species, including chickens, pigs, cattle and even fish

• A very large market that can be effectively accessed by Avivagen

6

1st Tech: Livestock Opportunities

For Terrestrial Livestock and Aquaculture Species– Protect general health– Improve growth rates and feed conversion– Prevent losses from bacterial diseases

To International Compound Feed Market– Approx. 950 million tons of annual feed usage– Addition of just grams of active per ton of feed– Multiple feeding protocols under development

7

1st Tech: Pets via Veterinarians

• Oximunol™ Chewable Tablets

• For dogs, in the United States

• Available from veterinarians via Bayer Animal Health

• 150 sales reps, 84,000 veterinarians, 83M dogs

8

1st Tech: Pets via Consumers

• Vivamune™ Health Chews for large dogs, smaller dogs and cats

• The Avivagen direct-to-consumer product format – a re-sealable bag of 30 chews.

• Marketing in ”Modern Dog” & “Cesar’s Way” magazines, other channels.

• Available on-line in the U.S. from www.vivamunehealth.com

9

1st Tech: Pet Opportunities

For Dogs, Cats and other non-food animals– Protect general health– Improve coat quality & reduce shedding– Increase mobility & interest in activities

To Pet Supplement and Pet Food markets– Now available in the United States– Usage in supplements like Oximunol & Vivamune– Potential for inclusion into branded pet foods

10

2nd Tech: Sterilization

• Permanent & Non-Surgical Sterilization– Invented by the Dir. of Canada’s largest vet hospital– A novel approach that may replace spaying– Exclusively optioned to Avivagen

• Potential to be a blockbuster veterinary product– Currently no alternative to surgery for spaying– Product would be the first to meet this urgent need– U.S. market of 89 million female dogs and cats

11

2nd Tech: Overview of Invention

• Characteristics of Invention– A drug-based approach (non-hormone, non-vaccine)– Would result in permanent sterility– Would be a simple and single administration

• Next Steps in Development Process– Design and conduct in vivo proof of concept work– Undertake global patenting of the invention– Begin species-specific product development work

12

2nd Tech: Option Agreement

• Structure of Option Agreement– A 12-month option to evaluate the invention– Support of proof-of-concept and patenting work– No other payment or dilution incurred under the option

• Terms of Definitive Licensing (if option exercised)– Issuance of 1.4 M shares & 5.0 M warrants (above market)– Royalty of 1% on sales in excess of $10 million– Two step approach minimizes risk and cost to Avivagen

13

Key Developments in LTM

• Completion of refinancing (Nov. 2013)• 1st Publication on OxC-beta (Feb. 2014)• Vietnam swine trial started (Mar. 2014)• Korea poultry trial started (Mar. 2014) • Recruitment of new Chairman (Apr. 2014)• Optioning of Sterilization Tech (Jul. 2014)

14

Management

• Capable Senior Team:– Kym Anthony – Chairman of the Board– Cameron Groome – CEO & President– C. Boland – CFO– G. Burton – Director, Commercialization Science– J. Daroszewski – Director, Product Devel. & Q.A.– D. Hankinson – Executive Director– J. Nickerson – Director, Product Validation– W. Riley – International Business Development

15

CEO Biography

• 23 years of life sciences experience– 10 years as a ranked sell-side analyst– 6 years as a leading investment banker– 6 years as EVP of public veterinary Co.– Active advisor & board member

– Proven operations, deal making and capital markets capabilities

16

Corporate Goals

• Near-term objectives are as follows:

– Establish marketable livestock feed protocols– Generate livestock registrations and sales– Support U.S. dog & cat product marketing– Further publication of OxC-beta discoveries– Proofs of concept on sterilization technology– Achieve sales & business development milestones– Communicate progress to capital markets

17

Economic Potential

• 1st Technology – Immune Enhancement – Can rapidly scale production of OxC-beta active– To define successful protocols for livestock producers– Enough supply to supplement 5-10 million tons of feed

• 2nd Technology – Sterilization– In the U.S., for replacement of 78 M spaying surgeries– Cost of spaying typically US$100-300 per animal– Also large feral/wild animal and livestock opportunities

18

Company Highlights

Two Technologies with Large Sales Potential

1. Enhancement of Immunity against bacteria– Discovery of a new class of natural compounds

– As an alternative to the use of antibiotics in livestock feeds

– As a health supplement for companion animals

2. Permanent Non-Surgical Sterilization– Means to replace spaying for population control

– Potentially applicable to all female mammals

– Uses for dogs, cats, feral/wild animals and livestock

19

Capital Markets - Summary

Ticker / Exchange VIV on TSXV

Recent Price $0.065

Market Cap $11.0 million

52 week Hi-Low $0.11 -$0.06

Shares outstanding (basic) 171 M

Average daily volume (last 3

months) 80,000 shares

Share ownership

Insiders: ~10%Pathfinder Asset Management:

~10%Bloom Burton & Co.: <10%

Float: ~70%

Burn rate$170,000/month

(excludes any cash flow from products)

20

Capital Markets - Comparables

Company / Ticker Market Cap

Afexa (acquired) $90 M

Atrium (acquired) $754 M

Bioniche Animal Health (acquired) $61 M

Acasti (TSXV:APO) $116 M

Burcon (TSX:BU) $138 M

Neptune (TSX:NTB) $199 M

SunOpta (TSX:SOY) $979 M

Average: $334 M

Median: $138 M

Avivagen (TSXV:VIV) $11 M

21

www.avivagen.com

Science is in our nature